Related Experiment Video
Updated: May 19, 2026

Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
Published on: June 30, 2019
Characterization of ML-IAP protein stability and physiological role in vivo
Eugene Varfolomeev1, Elham Moradi, Jasmin N Dynek
1Department of Early Discovery Biochemistry, Genentech Inc., South San Francisco, CA 94080, USA.
Abstract:
ML-IAP [melanoma IAP (inhibitor of apoptosis)] is an anti-apoptotic protein that is expressed highly in melanomas where it contributes to resistance to apoptotic stimuli. The anti-apoptotic activity and elevated expression of IAP family proteins in many human cancers makes IAP proteins attractive targets for inhibition by cancer therapeutics. Small-molecule IAP antagonists that bind with high affinities to select BIR (baculovirus IAP repeat) domains have been shown to stimulate auto-ubiquitination and rapid proteasomal degradation of c-IAP1 (cellular IAP1) and c-IAP2 (cellular IAP2). In the present paper, we report ML-IAP proteasomal degradation in response to bivalent, but not monovalent, IAP antagonists. This degradation required ML-IAP ubiquitin ligase activity and was independent of c-IAP1 or c-IAP2. Although ML-IAP is best characterized in melanoma cells, we show that ML-IAP expression in normal mammalian tissues is restricted largely to the eye, being most abundant in ciliary body epithelium and retinal pigment epithelium. Surprisingly, given this pattern of expression, gene-targeted mice lacking ML-IAP exhibited normal intraocular pressure as well as normal retinal structure and function. The results of the present study indicate that ML-IAP is dispensable for both normal mouse development and ocular homoeostasis.
Insights
Melanoma inhibitor of apoptosis (ML-IAP) protein degradation is induced by bivalent antagonists, independent of other IAPs. ML-IAP is dispensable for normal mouse development and eye homeostasis.
Area of Science:
- Molecular biology
- Cancer research
- Ophthalmology
Background:
- Melanoma inhibitor of apoptosis (ML-IAP) is an anti-apoptotic protein highly expressed in melanomas, contributing to therapeutic resistance.
- Inhibitor of Apoptosis (IAP) proteins are attractive targets for cancer therapeutics due to their roles in cancer progression.
- Small-molecule IAP antagonists targeting baculovirus IAP repeat (BIR) domains can induce proteasomal degradation of c-IAP1 and c-IAP2.
Purpose of the Study:
- To investigate the degradation of ML-IAP in response to IAP antagonists.
- To determine the role of ML-IAP in normal mammalian tissues, particularly the eye.
- To assess the necessity of ML-IAP for normal mouse development and ocular function.
Main Methods:
- Treatment of cells with bivalent and monovalent small-molecule IAP antagonists.
- Assessment of ML-IAP proteasomal degradation.
- Analysis of ML-IAP ubiquitin ligase activity.
- Examination of ML-IAP expression in normal mammalian tissues.
- Phenotypic analysis of gene-targeted mice lacking ML-IAP.
Main Results:
- ML-IAP undergoes proteasomal degradation in response to bivalent, but not monovalent, IAP antagonists.
- This degradation is dependent on ML-IAP's intrinsic ubiquitin ligase activity and independent of c-IAP1 or c-IAP2.
- ML-IAP expression in normal tissues is primarily restricted to the eye (ciliary body epithelium and retinal pigment epithelium).
- Mice lacking ML-IAP display normal intraocular pressure, retinal structure, and function.
Conclusions:
- Bivalent IAP antagonists can induce ML-IAP degradation through its own ubiquitin ligase activity.
- ML-IAP is not essential for maintaining normal ocular homeostasis or overall mouse development.
- ML-IAP may represent a therapeutic target in specific cancers, but its dispensability in normal tissues warrants further investigation.
Related Concept Videos
Bacterial Protein Maturation
RNA Stability
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability

